Log in

Relevant bibliographies by topics / MACE (major adverse cardiovascular events) / Journal articles

To see the other types of publications on this topic, follow the link: MACE (major adverse cardiovascular events).

Journal articles on the topic 'MACE (major adverse cardiovascular events)'

Author: Grafiati

Published: 5 June 2025

Last updated: 15 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'MACE (major adverse cardiovascular events).'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Ruiz, Juan I., Bo Zhao, Nicolas Palaskas, et al. "Major Adverse Cardiovascular Events in Patients with Melanoma Receiving Immune Checkpoint Inhibitors." Journal of Immunotherapy and Precision Oncology 8, no. 2 (2025): 1–9. https://doi.org/10.36401/jipo-24-31.

Full text

Abstract:

ABSTRACT Introduction Immune checkpoint inhibitors (ICIs) might increase the risk of major adverse cardiovascular events (MACEs). This study aimed to evaluate the risk of MACE in patients with melanoma after ICI initiation. Methods We conducted a before-after cohort study using claims data from Optum’s deidentified Clinformatics Data Mart Database. We included adult patients with melanoma who received any approved ICI between 2011 and 2021 with a minimum of 12 months of observable data before ICI. The main outcome was time to first MACE (myocardial infarction, coronary revascularization, strok

APA, Harvard, Vancouver, ISO, and other styles

2

Shin, Hong-Joon, Joon-Young Yoon, Young-Ok Na, et al. "Major adverse cardiovascular events and hyperuricemia during tuberculosis treatment." PLOS ONE 18, no. 11 (2023): e0294490. http://dx.doi.org/10.1371/journal.pone.0294490.

Full text

Abstract:

Background Hyperuricemia is common during tuberculosis (TB) treatment, especially in association with pyrazinamide (PZA). This study investigated the relationship between major adverse cardiovascular events (MACEs) and hyperuricemia during TB treatment. Methods We conducted a single-center retrospective cohort study. From January 2010 through June 2017, we assessed all consecutive TB patients at Chonnam National University Hospital in South Korea. Hyperuricemia was defined as serum uric acid levels exceeding 7.0 mg/dL (men) and 6.0 mg/dL (women). Results Of the 1,143 patients included, PZA was

APA, Harvard, Vancouver, ISO, and other styles

3

Lee, Andrew, Jacqueline Henry, and Stuart Atkinson. "Major adverse cardiovascular event risk following androgen deprivation therapy initiation by personal history of cardiovascular events." Journal of Clinical Oncology 41, no. 6_suppl (2023): 351. http://dx.doi.org/10.1200/jco.2023.41.6_suppl.351.

Full text

Abstract:

351 Background: Associations between androgen deprivation therapy (ADT) and increased cardiovascular (CV) risk in prostate cancer (PCa) patients have been reported; however, how many of these major adverse CV events (MACE) are caused by ADT itself has been debated. One risk factor for increased CV risk is a prior history of CV events; an analysis found that each new CV event increased the probability of a future event. This study aims to evaluate the incidence of MACE after ADT initiation for patients with and without a prior medical history of MACE. Methods: Analyses of US electronic medical

APA, Harvard, Vancouver, ISO, and other styles

4

Oh, Tak-Kyu, Hyoung-Won Cho, and In-Ae Song. "Association of Opioid Prescription with Major Adverse Cardiovascular Events: Nationwide Cohort Study." Journal of Clinical Medicine 14, no. 4 (2025): 1205. https://doi.org/10.3390/jcm14041205.

Full text

Abstract:

Background: This study aimed to investigate the association between opioid use and the incidence of major adverse cardiovascular events (MACEs). Methods: This study included adult patients who had received oral or transdermal opioids in 2016. The control group comprised individuals who did not receive opioids in 2016 and was selected using a 1:1 stratified random sampling procedure. A MACE was defined as the occurrence of acute myocardial infarction, stroke, heart failure, or cardiovascular mortality. The primary endpoints were new MACEs and cardiovascular mortality, as evaluated from 1 Januar

APA, Harvard, Vancouver, ISO, and other styles

5

Noumegni, Steve Raoul, Romain Didier, Vincent Mansourati, et al. "Risk Factors for Major Adverse Cardiovascular Events and Major Adverse Limb Events after Venous Thromboembolism: A Large Prospective Cohort Study." Seminars in Thrombosis and Hemostasis 48, no. 04 (2022): 465–80. http://dx.doi.org/10.1055/s-0042-1748152.

Full text

Abstract:

Abstract Background There is an increased risk of arterial events including major adverse cardiovascular events (MACE) and major adverse limb events (MALE) after venous thromboembolism (VTE). However, their risk factors remain little explored. Methods We aimed to determine the risk factors for MACE (acute coronary syndrome/stroke/cardiovascular death) and MALE (limb ischemia/critical limb ischemia/non-traumatic amputation/any limb revascularization) after VTE. Competing risk models (Fine-Gray) were used in a multicenter prospective cohort of 4,940 patients (mean age: 64.6 years and median foll

APA, Harvard, Vancouver, ISO, and other styles

6

Niiranen, Oskari, Juha Virtanen, Ville Rantasalo, Amer Ibrahim, Maarit Venermo, and Harri Hakovirta. "The Association between Major Adverse Cardiovascular Events and Peripheral Artery Disease Burden." Journal of Cardiovascular Development and Disease 11, no. 6 (2024): 157. http://dx.doi.org/10.3390/jcdd11060157.

Full text

Abstract:

Objective: The aim of the present study was to investigate the possible relationship between the segmental burden of lower limb atherosclerosis and Major Adverse Cardiovascular Events (MACEs). Methods: All the consecutive symptomatic peripheral artery disease (PAD) patients admitted for digital subtraction angiography (DSA) at Turku University Hospital department of Vascular Surgery between 1 January 2009 and 30 July 2011 were retrospectively analyzed. Angiography due to symptomatic PAD was used as the index date for the inclusion in the study. The segmental burden of atherosclerosis based on

APA, Harvard, Vancouver, ISO, and other styles

7

van der Woude, J., S. Schreiber, L. Peyrin-Biroulet, et al. "P520 Thromboembolic and major adverse cardiovascular events among patients in the filgotinib clinical trial programme." Journal of Crohn's and Colitis 17, Supplement_1 (2023): i646—i649. http://dx.doi.org/10.1093/ecco-jcc/jjac190.0650.

Full text

Abstract:

Abstract Background The once-daily, oral, Janus kinase 1 preferential inhibitor filgotinib (FIL) is approved for the treatment of moderately to severely active rheumatoid arthritis (RA) and ulcerative colitis (UC) in the UK, the EU and Japan.1 To further understand the safety profile of FIL across indications, we evaluated the risk of major adverse cardiovascular events (MACEs) and venous thromboembolic events (VTEs) in patients treated with FIL 200 mg (FIL200) or FIL 100 mg (FIL100). Methods An integrated analysis was conducted with RA data from five phase 2/3 trials and two long-term extensi

APA, Harvard, Vancouver, ISO, and other styles

8

Moltó-Balado, Pedro, Silvia Reverté-Villarroya, Victor Alonso-Barberán, et al. "Machine Learning Approaches to Predict Major Adverse Cardiovascular Events in Atrial Fibrillation." Technologies 12, no. 2 (2024): 13. http://dx.doi.org/10.3390/technologies12020013.

Full text

Abstract:

The increasing prevalence of atrial fibrillation (AF) and its association with Major Adverse Cardiovascular Events (MACE) presents challenges in early identification and treatment. Although existing risk factors, biomarkers, genetic variants, and imaging parameters predict MACE, emerging factors may be more decisive. Artificial intelligence and machine learning techniques (ML) offer a promising avenue for more effective AF evolution prediction. Five ML models were developed to obtain predictors of MACE in AF patients. Two-thirds of the data were used for training, employing diverse approaches

APA, Harvard, Vancouver, ISO, and other styles

9

Wei, Kai-Che, Cheng-Len Sy, Wen-Hwa Wang, Chia-Ling Wu, Shang-Hung Chang, and Yu-Tung Huang. "Major acute cardiovascular events after dengue infection–A population-based observational study." PLOS Neglected Tropical Diseases 16, no. 2 (2022): e0010134. http://dx.doi.org/10.1371/journal.pntd.0010134.

Full text

Abstract:

Background Dengue virus (DENV) infection may be associated with increased risks of major adverse cardiovascular effect (MACE), but a large-scale study evaluating the association between DENV infection and MACEs is still lacking. Methods and findings All laboratory confirmed dengue cases in Taiwan during 2009 and 2015 were included by CDC notifiable database. The self-controlled case-series design was used to evaluate the association between DENV infection and MACE (including acute myocardial infarction [AMI], heart failure and stroke). The "risk interval" was defined as the first 7 days after

APA, Harvard, Vancouver, ISO, and other styles

10

Villegas-Quintero, Víctor Eder, Rodolfo Rivas-Ruíz, Alexis Alejandro García-Rivero, Pedro Rivera-Lara, and Nelly Berenice González-Tovar. "[Efficacy and safety of atorvastatin in major cardiovascular events: Meta-analysis]." Revista Médica del Instituto Mexicano del Seguro Social 61, Suppl 3 (2023): S407—S415. https://doi.org/10.5281/zenodo.8319748.

Full text

Abstract:

<strong>Abstract </strong><strong>Introduction:</strong> Atorvastatin has been used in the management of dyslipidemia and little is known about the efficacy and safety of high-dose atorvastatin administration for secondary prevention of Major Cardiovascular Events (MACE).Objective: To evaluate the impact of high-dose atorvastatin on secondary prevention of MACE and adverse events.<strong>Material and methods:</strong> A systematic review and meta-analysis of Pubmed, Embase, Bireme and Cochrane Library Plus databases was performed, with a time scope from 1990 to July 2022. Six randomized c

APA, Harvard, Vancouver, ISO, and other styles

11

Goyal, Abhinav, Kshitij Chatterjee, Roy O. Mathew, et al. "In-Hospital Mortality and Major Adverse Cardiovascular Events after Kidney Transplantation in the United States." Cardiorenal Medicine 9, no. 1 (2018): 51–60. http://dx.doi.org/10.1159/000492731.

Full text

Abstract:

Background: Kidney transplantation (KT) is the treatment of choice for end-stage kidney disease. Cardiovascular disease is a major determinant of morbidity and mortality in patients with KT. Temporal trends in perioperative cardiovascular outcomes after KT are understudied, especially in light of an aging KT waitlist population. Methods: We performed a retrospective observational cohort study using the National Inpatient Sample for the years 2004–2013. All adult patients undergoing KT were identified using the appropriate International Classification of Diseases, 9th Revision, Clinical Modific

APA, Harvard, Vancouver, ISO, and other styles

12

Twardowski, Przemyslaw, Jacqueline Henry, and Stuart Atkinson. "Major adverse cardiovascular events after androgen deprivation therapy in patients with prostate cancer with hypercholesterolemia." Journal of Clinical Oncology 41, no. 6_suppl (2023): 348. http://dx.doi.org/10.1200/jco.2023.41.6_suppl.348.

Full text

Abstract:

348 Background: Prostate cancer (PCa) patients treated with androgen deprivation therapy (ADT) may experience major adverse cardiovascular events (MACE). It is unclear how much of MACE is caused by ADT itself. High cholesterol has been associated with lower MACE risk in older men, not on statin therapy. This study evaluates MACE risk after ADT initiation for patients with and without hypercholesterolemia using real-world data. Methods: US electronic medical records (2010-2020) of PCa patients (n=45,059) receiving LHRH agonist/antagonist injections were analyzed to calculate the risk of MACE si

APA, Harvard, Vancouver, ISO, and other styles

13

Karpouzas, George Athanasios, Sarah R. Ormseth, Piet Leonardus Cornelis Maria van Riel, et al. "Biological use influences the impact of inflammation on risk of major adverse cardiovascular events in rheumatoid arthritis." RMD Open 10, no. 3 (2024): e004546. http://dx.doi.org/10.1136/rmdopen-2024-004546.

Full text

Abstract:

ObjectivesChronic inflammation promotes cardiovascular risk in rheumatoid arthritis (RA). Biological disease-modifying antirheumatic drugs (bDMARDs) improve disease activity and cardiovascular disease outcomes. We explored whether bDMARDs influence the impact of disease activity and inflammatory markers on long-term cardiovascular risk in RA.MethodsWe studied 4370 participants without cardiovascular disease in a 10-country observational cohort of patients with RA. Endpoints were (1) major adverse cardiovascular events (MACE) encompassing myocardial infarction, stroke and cardiovascular death;

APA, Harvard, Vancouver, ISO, and other styles

14

Sposato, Luciano A., Melody Lam, Britney Allen, Salimah Z. Shariff, and Gustavo Saposnik. "First-Ever Ischemic Stroke and Incident Major Adverse Cardiovascular Events in 93 627 Older Women and Men." Stroke 51, no. 2 (2020): 387–94. http://dx.doi.org/10.1161/strokeaha.119.028066.

Full text

Abstract:

Background and Purpose— Stroke risk is sex-specific, but little is known about sex differences of poststroke major adverse cardiovascular events (MACEs). Stroke-related brain damage causes autonomic dysfunction and inflammation, sometimes resulting in cardiac complications. Sex-specific cardiovascular susceptibility to stroke without the confounding effect of preexisting heart disease constitutes an unexplored field because previous studies focusing on sex differences in poststroke MACE have not excluded patients with known cardiovascular comorbidities. We therefore investigated sex-specific r

APA, Harvard, Vancouver, ISO, and other styles

15

Kozlova, Dariya, Colin Gimblet, Linder Wendt, et al. "Vascular dysfunction is associated with major adverse cardiovascular events in prediabetes: A cohort study." PLOS One 20, no. 6 (2025): e0324945. https://doi.org/10.1371/journal.pone.0324945.

Full text

Abstract:

Background Prediabetes is a growing public health concern that increases the risk of major adverse cardiovascular events (MACE). Vascular dysfunction worsens with hyperglycemia and is associated with MACE in several high-risk populations. However, it is unknown whether vascular dysfunction contributes to MACE in prediabetes. We hypothesized that vascular dysfunction is associated with elevated risk of MACE in prediabetes. Methods We conducted an observational study of 5742 adults (age 54.9 ± 11.5 years, 54% female) in the Framingham Offspring and Generation III cohorts. Prediabetes was defined

APA, Harvard, Vancouver, ISO, and other styles

16

Choi, Dong-Hyun, Yuhei Kobayashi, Takeshi Nishi, et al. "Combination of Mean Platelet Volume and Neutrophil to Lymphocyte Ratio Predicts Long-Term Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention." Angiology 70, no. 4 (2018): 345–51. http://dx.doi.org/10.1177/0003319718768658.

Full text

Abstract:

We hypothesized that the combination of a high neutrophil to lymphocyte ratio (NLR) and mean platelet volume (MPV) would be a stronger predictor of future cardiovascular events after percutaneous coronary intervention (PCI). Both NLR and MPV were measured in 364 consecutive patients undergoing PCI. The primary end point was the incidence of major adverse cardiovascular events (MACEs), including cardiac death, nonfatal myocardial infarction, and stent thrombosis. The median values of NLR and MPV were 2.8 and 8.2 fL, respectively. There were 26 MACEs during a median follow-up duration of 29.3 mo

APA, Harvard, Vancouver, ISO, and other styles

17

Rydman, Riikka, Yumi Shiina, Gerhard-Paul Diller, et al. "Major adverse events and atrial tachycardia in Ebstein’s anomaly predicted by cardiovascular magnetic resonance." Heart 104, no. 1 (2017): 37–44. http://dx.doi.org/10.1136/heartjnl-2017-311274.

Full text

Abstract:

ObjectivesPatients with Ebstein’s anomaly of the tricuspid valve (EA) are at risk of tachyarrhythmia, congestive heart failure and sudden cardiac death. We sought to determine the value of cardiovascular magnetic resonance (CMR) for predicting these outcomes.MethodsSeventy-nine consecutive adult patients (aged 37±15 years) with unrepaired EA underwent CMR and were followed prospectively for a median 3.4 (range 0.4–10.9) years for clinical outcomes, namely major adverse cardiovascular events (MACEs: sustained ventricular tachycardia/heart failure hospital admission/cardiac transplantation/death

APA, Harvard, Vancouver, ISO, and other styles

18

Yang, Aram, Sinae Kim, and Yong Jun Choi. "Impact of Nontreatment Duration and Keratopathy on Major Adverse Cardiovascular Events in Fabry Disease: A Nationwide Cohort Study." Journal of Clinical Medicine 13, no. 2 (2024): 479. http://dx.doi.org/10.3390/jcm13020479.

Full text

Abstract:

Fabry disease (FD) is a rare inherited X-linked lysosomal storage disorder that results in the progressive accumulation of glycosphingolipids in multiple organs. Early FD-specific treatments may improve clinical outcomes; however, clinical evidence about early FD treatment is limited. We aimed to determine the cardiovascular outcomes of patients with FD who received enzyme replacement therapy. This nationwide observational study was conducted using the National Health Claims database of the Korean population with FD. The primary outcome was major adverse cardiovascular events (MACEs). MACE ris

APA, Harvard, Vancouver, ISO, and other styles

19

Ioannides, A. E., E. L. Graul, and J. K. Quint. "Adverse Events Following Major Adverse Cardiovascular Events(MACE) in People With COPD: An Analysis of Exacerbations, MACE and Mortality." American Journal of Respiratory and Critical Care Medicine 211, Abstracts (2025): A6191. https://doi.org/10.1164/ajrccm.2025.211.abstracts.a6191.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Li, Ben, Farah Shaikh, Abdelrahman Zamzam, Rawand Abdin, and Mohammad Qadura. "Inflammatory Biomarkers to Predict Major Adverse Cardiovascular Events in Patients with Carotid Artery Stenosis." Medicina 60, no. 6 (2024): 997. http://dx.doi.org/10.3390/medicina60060997.

Full text

Abstract:

Background and Objectives: Inflammatory proteins and their prognostic value in patients with carotid artery stenosis (CAS) have not been adequately studied. Herein, we identified CAS-specific biomarkers from a large pool of inflammatory proteins and assessed the ability of these biomarkers to predict adverse events in individuals with CAS. Materials and Methods: Samples of blood were prospectively obtained from 336 individuals (290 with CAS and 46 without CAS). Plasma concentrations of 29 inflammatory proteins were determined at recruitment, and the patients were followed for 24 months. The ou

APA, Harvard, Vancouver, ISO, and other styles

21

Shenoy, B., N. McArdle, J. Walsh, et al. "P109 Predicting major adverse cardiovascular events using symptom subtypes of severe obstructive sleep apnoea." SLEEP Advances 3, Supplement_1 (2022): A65. http://dx.doi.org/10.1093/sleepadvances/zpac029.179.

Full text

Abstract:

Abstract Background Obstructive sleep apnoea (OSA) is a complex heterogeneous disorder, and patients with similar disease severity present with different symptom profiles and outcomes. It is unclear whether OSA symptom subtypes independently predict incident major adverse cardiovascular events (MACE). Method Consecutive patients attending a tertiary sleep clinic from 2006 to 2010 were prospectively investigated and linked to administrative health data. Data from 1,767 patients with severe OSA (apnoea-hypopnoea index ≥30 events/hour) were used in latent class analysis to identify symptom subtyp

APA, Harvard, Vancouver, ISO, and other styles

22

Dabić, Petar, Jovan Petrović, Bojan Vučurević, et al. "Major adverse cardiac events in vascular surgery patients with peripheral arterial disease." Medicinska istrazivanja 57, no. 1 (2024): 9–13. http://dx.doi.org/10.5937/medi57-47260.

Full text

Abstract:

Introduction: Major adverse cardiac events (MACE) are the primary cause of morbidity and mortality in patients undergoing vascular surgical procedures. This is why it is essential to understand the relationship between coronary artery disease and peripheral arterial disease. In this paper, we aimed to determine predictors and risk factors related to the occurrence of MACE in patients undergoing vascular surgery for peripheral arterial disease. Material and Methods: This is a retrospective study of 310 in-hospital patients treated at a high-volume vascular centre. The outcome was classified thr

APA, Harvard, Vancouver, ISO, and other styles

23

Morrison, Justin T., Nicholas Govsyeyev, Connie N. Hess, and Marc P. Bonaca. "Vorapaxar for Prevention of Major Adverse Cardiovascular and Limb Events in Peripheral Artery Disease." Journal of Cardiovascular Pharmacology and Therapeutics 27 (January 1, 2022): 107424842110561. http://dx.doi.org/10.1177/10742484211056115.

Full text

Abstract:

Peripheral artery disease (PAD) is a severe manifestation of atherosclerosis. Patients with PAD are at heightened risk for atherothrombotic complications, including myocardial infarction and stroke (MACE); however, there is also an equal or greater risk of major adverse limb events (MALE), such as acute limb ischemia (ALI) and major amputation. Therefore, there is a need for effective medical therapies to reduce the risk of both MACE and MALE. Recent trials have demonstrated the role of thrombin inhibition in reducing the risk of MACE and MALE in PAD patients. One such medical therapy, vorapax

APA, Harvard, Vancouver, ISO, and other styles

24

Savic, Lidija, Damjan Simic, Ratko Lasica, et al. "Predictors of Major Adverse Cardiovascular Events in Stable Patients After ST Elevation Myocardial Infarction." Clinics and Practice 15, no. 6 (2025): 106. https://doi.org/10.3390/clinpract15060106.

Full text

Abstract:

Background/aim: The aim of this study was to determine predictors of major adverse cardiovascular events, including MACE (mortality, non-fatal recurrent infarction, non-fatal stroke, and target vessel revascularization-TVR) in stable post-STEMI patients. Method: We analyzed STEMI patients without cardiogenic shock at admission included in our STEMI Register. The patients were treated with primary PCI. The follow-up period was eight years. Results: From 1 December 2006 to 31 December 2016, a total of 3079 patients were included in the Register. In the first year, MACE was registered in 348 (11.

APA, Harvard, Vancouver, ISO, and other styles

25

Gordan, Lucio N., Stuart Atkinson, Deborah Boldt-Houle, and Andrew K. Lee. "Comparison of major adverse cardiovascular events risk after androgen deprivation therapy initiation by body mass index." Journal of Clinical Oncology 40, no. 6_suppl (2022): 44. http://dx.doi.org/10.1200/jco.2022.40.6_suppl.044.

Full text

Abstract:

44 Background: The association between androgen deprivation therapy (ADT) and increased cardiovascular (CV) risk in prostate cancer (PCa) patients is controversial.1-2 Major adverse cardiovascular events (MACE) occurred in 3-6% of patients in a 48-week ADT trial,2 but meta-analysis from a 2011 study found no association between ADT and increased risk of CV death.1 Body mass index (BMI) is a potential risk factor; Lee et al. found a lower risk of MACE in patients with high BMI than those with a normal weight, and patients with low BMI had a higher risk of all-cause mortality.3 This study evalua

APA, Harvard, Vancouver, ISO, and other styles

26

Rui Lam, Amanda Yun, Min Min Chan, David Carmody, et al. "Predicting Major Adverse Cardiovascular Events in Asian Type 2 Diabetes Patients With Lasso-Cox Regression." Journal of the Endocrine Society 5, Supplement_1 (2021): A417—A418. http://dx.doi.org/10.1210/jendso/bvab048.852.

Full text

Abstract:

Abstract Background: South-East Asia has seen a dramatic increase in type 2 diabetes (T2D). Risk prediction models for Major adverse cardiovascular events (MACE) identify patients who may benefit most from intensive prevention strategies. Existing risk prediction models for T2D were developed mainly in Caucasian populations, limiting their generalizability to Asian populations. We developed a Lasso-Cox regression model to predict the 5-year risk of incident MACE in Asian patients with T2DM using data from the largest diabetes registry in Singapore. Methodology: The diabetes registry contained

APA, Harvard, Vancouver, ISO, and other styles

27

Hung, Wei-Chin, Teng-Hung Yu, Chia-Chang Hsu, et al. "Plasma visfatin levels are associated with major adverse cardiovascular events in patients with acute ST-elevation myocardial infarction." Clinical & Investigative Medicine 38, no. 3 (2015): 100. http://dx.doi.org/10.25011/cim.v38i3.22705.

Full text

Abstract:

Purpose: Circulating levels of visfatin, a ubiquitous adipokine, may reflect both the severity of plaque as well as degree of plaque stabilization in acute myocardial injury. The purpose of this study was to test whether the level of visfatin is associated with the occurrence of major adverse cardiovascular events (MACEs) in patients with acute ST-elevation myocardial infarction (STEMI). Methods: Consecutive patients (n=185) with acute STEMI were prospectively enrolled in the study. ELISA was used to measure plasma visfatin concentrations. Composite MACEs included death, recurrent myocardial i

APA, Harvard, Vancouver, ISO, and other styles

28

Niu, Qiang, Zhongsu Wang, Yong Zhang, et al. "Combination Use of Clopidogrel and Proton Pump Inhibitors Increases Major Adverse Cardiovascular Events in Patients With Coronary Artery Disease." Journal of Cardiovascular Pharmacology and Therapeutics 22, no. 2 (2016): 142–52. http://dx.doi.org/10.1177/1074248416663647.

Full text

Abstract:

Background: Published data indicated that combination use of clopidogrel and proton pump inhibitors (PPIs) may increase the incidence of major adverse cardiovascular events (MACEs). This has been a highly controversial topic for years. Design: The present study was performed to evaluate whether combination therapy of clopidogrel and PPIs is associated with increased risk of MACEs than with clopidogrel alone in patients with coronary artery disease. Methods: A systematic search of MEDLINE, EMBASE, and the Cochrane Library was conducted for studies recording the occurrence of MACEs in patients w

APA, Harvard, Vancouver, ISO, and other styles

29

Li, Ben, Farah Shaikh, Houssam Younes, et al. "Prediction of Major Adverse Cardiovascular Events in Patients with Peripheral Artery Disease Using Circulating Immunomodulatory Proteins." Biomedicines 12, no. 12 (2024): 2842. https://doi.org/10.3390/biomedicines12122842.

Full text

Abstract:

Background/Objectives: The leading cause of death for people with peripheral artery disease (PAD) is major adverse cardiovascular events (MACE), including heart attacks and strokes. However, research into biomarkers that could help predict MACE in patients with PAD has been limited. Immunomodulatory proteins are known to significantly influence systemic atherosclerosis, suggesting they could be useful prognostic indicators for MACE in patients with PAD. In this study, we evaluated a broad panel of immunomodulatory proteins to identify those linked to MACE in individuals with PAD. Methods: We c

APA, Harvard, Vancouver, ISO, and other styles

30

Shen, Yun, Xueli Zhang, Yiting Xu, et al. "Serum FGF21 Is Associated with Future Cardiovascular Events in Patients with Coronary Artery Disease." Cardiology 139, no. 4 (2018): 212–18. http://dx.doi.org/10.1159/000486127.

Full text

Abstract:

Objectives: To investigate whether serum fibroblast growth factor 21 (FGF21) levels can be used to predict the future development of major adverse cardiovascular events (MACEs). Methods: This study included 253 patients who received subsequent follow-up, and complete data were collected for 234 patients. Independent predictors of MACEs were identified by using the Cox proportional-hazards regression analysis. The prognostic value of FGF21 levels for MACEs was evaluated by Kaplan-Meier survival analysis. Results: Of 229 patients finally enrolled in the analysis, 27/60 without coronary artery di

APA, Harvard, Vancouver, ISO, and other styles

31

Wheless, Lee, Ranya Guennoun, Basia Michalski-McNeely, et al. "Risk of Major Adverse Cardiovascular Events Following Nicotinamide Exposure." JAMA Dermatology, February 26, 2025. https://doi.org/10.1001/jamadermatol.2025.0001.

Full text

Abstract:

ImportanceNicotinamide metabolites have recently been implicated in increased risk of major cardiovascular events (MACE). Supportive data about clinical risk of MACE for nicotinamide users is lacking.ObjectiveTo determine whether nicotinamide use results in an increase of MACE.Design, Setting, and ParticipantsThis study used retrospective electronic health record data of 2 patient cohorts, the Vanderbilt University Medical Center (VUMC) and Million Veteran Program (MVP). The risk of MACE in patients exposed to nicotinamide was compared with the risk of MACE in unexposed patients. In the VUMC c

APA, Harvard, Vancouver, ISO, and other styles

32

Adjei‐Frimpong, Nana Ama, Francesco Delacqua, Ben A. Croker, and Reid Oldenburg. "Pyoderma Gangrenosum Associated With Major Adverse Cardiovascular Events." JEADV Clinical Practice, July 9, 2025. https://doi.org/10.1002/jvc2.70114.

Full text

Abstract:

ABSTRACTBackgroundPyoderma gangrenosum (PG) is a neutrophilic dermatosis characterized by the rapid onset of painful ulcers. Previous retrospective population‐based studies have identified a relationship between PG and major adverse cardiovascular events (MACE). However, these studies lacked appropriate control groups and were not conducted in the United States (US).ObjectivesThis study examines the association between PG and MACE using the All of Us (AoU) database, a nationwide initiative created to increase research in underrepresented populations.MethodsWe performed a nested case‐control st

APA, Harvard, Vancouver, ISO, and other styles

33

Omari, Ramsey, Charles Curtis, Nichole Burket, Michael Weisman, Xiaofeng Chen, and Tim Lautenschlaeger. "Major Adverse Cardiac Events After Radiation Therapy in Lung Cancer." Proceedings of IMPRS 4, no. 1 (2021). http://dx.doi.org/10.18060/25761.

Full text

Abstract:

Motivation:  Receiving radiation to the heart has been recognized as a risk factor for the development of major adverse cardiovascular events (MACEs) for many years. However, recent data suggests that radiation dosing to substructures of the heart serve as a better surrogate for evaluating the risk of developing a MACE than whole heart radiation dose. Recent papers suggest that dosing to the left anterior descending artery (LAD) can be used as a robust marker for cardiotoxicity risk; however, this association lacks corroborative data and is currently not incorporated into clinically rout

APA, Harvard, Vancouver, ISO, and other styles

34

Liberman, Ava L., Junaid Razzak, Richard I. Lappin, et al. "Risk of Major Adverse Cardiovascular Events After Emergency Department Visits for Hypertensive Urgency." Hypertension, April 25, 2024. http://dx.doi.org/10.1161/hypertensionaha.124.22885.

Full text

Abstract:

BACKGROUND: Chronic hypertension is an established long-term risk factor for major adverse cardiovascular events (MACEs). However, little is known about short-term MACE risk after hypertensive urgency, defined as an episode of acute severe hypertension without evidence of target-organ damage. We sought to evaluate the short-term risk of MACE after an emergency department (ED) visit for hypertensive urgency resulting in discharge to home. METHODS: We performed a case-crossover study using deidentified administrative claims data. Our case periods were 1-week intervals from 0 to 12 weeks before h

APA, Harvard, Vancouver, ISO, and other styles

35

Gu, Z. S., Y. Huang, C. Costopoulos, et al. "Heterogeneous plaque geometry is associated with major adverse cardiovascular events." European Heart Journal 43, Supplement_2 (2022). http://dx.doi.org/10.1093/eurheartj/ehac544.1208.

Full text

Abstract:

Abstract Objectives To determine whether coronary artery plaque-lumen geometry predicts major adverse cardiovascular events (MACE), and incorporating geometric measures enhances risk stratification from intravascular imaging. Background Prospective studies show that only a minority of plaques with higher-risk features result in future MACE, indicating the need for more predictive markers of plaque vulnerability. Plaques show heterogeneous structures and plaque-lumen geometry, both of which can promote high plaque structural stress (PSS); however, the relationships between geometric heterogenei

APA, Harvard, Vancouver, ISO, and other styles

36

Gu, Sophie Z., Yuan Huang, Charis Costopoulos, et al. "Heterogeneous plaque-lumen geometry is associated with major adverse cardiovascular events." European Heart Journal Open, April 13, 2023. http://dx.doi.org/10.1093/ehjopen/oead038.

Full text

Abstract:

Abstract Aims Prospective studies show that only a minority of plaques with higher-risk features develop future major adverse cardiovascular events (MACE), indicating the need for more predictive markers. Biomechanical estimates such as plaque structural stress (PSS) improve risk prediction but require expert analysis. In contrast, complex and asymmetric coronary geometry is associated with both unstable presentation and high PSS, and can be estimated quickly from imaging. We examined whether plaque-lumen geometric heterogeneity evaluated from intravascular ultrasound affects MACE and incorpor

APA, Harvard, Vancouver, ISO, and other styles

37

Africano, Hector F., Cristian C. Serrano-Mayorga, Paula C. Ramirez-Valbuena, et al. "Major Adverse Cardiovascular Events During Invasive Pneumococcal Disease Are Serotype Dependent." Clinical Infectious Diseases, September 22, 2020. http://dx.doi.org/10.1093/cid/ciaa1427.

Full text

Abstract:

Abstract Background Up to 30% of patients admitted to hospitals with invasive pneumococcal disease (IPD) experience major adverse cardiovascular event (MACE) including new/worsening heart failure, new/worsening arrhythmia, and/or myocardial infarction. Streptococcus pneumoniae (Spn) is the most frequently isolated bacterial pathogen among community-acquired pneumonia (CAP) patients and the only etiological agent linked independently to MACE. Nevertheless, no clinical data exist identifying which serotypes of Spn are principally responsible for MACE. Methods This was an observational multicente

APA, Harvard, Vancouver, ISO, and other styles

38

Jain, Hritvik, Mohammed Dheyaa Marsool Marsool, Haleema Qayyum Abbasi, et al. "Association Between Fluoroquinolones and Major Adverse Cardiovascular Events: A Systematic Review." Cardiology in Review, April 30, 2024. http://dx.doi.org/10.1097/crd.0000000000000710.

Full text

Abstract:

Fluoroquinolones (FQs) are routinely administered antibiotics that have demonstrated an increased propensity to cause major adverse cardiovascular events (MACE). We conducted a systematic review aimed to investigate the association between FQ usage and the risk of MACE. A comprehensive literature search was conducted using PubMed, Scopus, and the Cochrane Library from inception to September 2023 to retrieve studies comparing FQ administration with placebo and reporting the occurrence of MACE. Relevant studies that explored the occurrence of MACE, defined as “acute myocardial infarction, stroke

APA, Harvard, Vancouver, ISO, and other styles

39

de Havenon, Adam, Richa Sharma, Daniel Sarpong, et al. "Abstract TMP25: Major Adverse Brain Events: Incidence Rates Of A Novel Composite Vascular Neurologic Outcome." Stroke 54, Suppl_1 (2023). http://dx.doi.org/10.1161/str.54.suppl_1.tmp25.

Full text

Abstract:

Background: The classical 3-point composite outcome MACE (major adverse cardiovascular events) includes incident stroke, myocardial infarction, and cardiovascular death. Conventional use of MACE may fail to account for important neurological consequences of vascular risk factors. We sought to report incidence rates of a novel composite neurologic outcome called major adverse brain events (MABE), comprised of incident stroke, dementia, and impaired balance in individuals with the vascular risk factor of hypertension. Methods: We analyzed TriNetX, the Health and Retirement Study (HRS), and Ather

APA, Harvard, Vancouver, ISO, and other styles

40

Goupil, Rémi, Louis-Charles Desbiens, Amel Merabtine, et al. "Subclinical Primary Aldosteronism and Major Adverse Cardiovascular Events: A Longitudinal Population-Based Cohort Study." Circulation, July 9, 2025. https://doi.org/10.1161/circulationaha.124.073507.

Full text

Abstract:

BACKGROUND: Primary aldosteronism (PA), an overt form of renin-independent aldosterone production, leads to a disproportionately high rate of major adverse cardiovascular events (MACEs). Mounting evidence suggests that milder forms of renin-independent aldosterone production (subclinical PA) are highly prevalent; however, the link between subclinical PA and MACE remains uncertain. METHODS: This prospective study included 2017 Canadian adults 40 to 69 years of age from the randomly sampled, population-based CARTaGENE cohort (Québec, Canada), in which aldosterone and renin concentrations at enro

APA, Harvard, Vancouver, ISO, and other styles

41

Esteve Pastor, M., F. Marin, M. Anguita, et al. "2MACE score predicts cardiovascular adverse events in real-world atrial fibrillation patients under rivaroxaban therapy. Data from EMIR study." European Heart Journal 42, Supplement_1 (2021). http://dx.doi.org/10.1093/eurheartj/ehab724.2484.

Full text

Abstract:

Abstract Background Atrial Fibrillation (AF) patients have higher risk of major adverse cardiovascular events (MACEs). In 2015, the 2MACE score (2 points for metabolic syndrome and age ≥75, and 1 point for myocardial infarction [MI] or revascularization, congestive heart failure [ejection fraction ≤40%] and thromboembolism [stroke or transient ischemic attack]) was described to stratify cardiovascular risk and 2MACE≥3 was related with high risk of MACE in AF patients but a long-term validation in prospective patients under direct anticoagulants has not been performed yet. The aim of this study

APA, Harvard, Vancouver, ISO, and other styles

42

Takase, H., M. Machii, D. Nonaka, et al. "P1545Predictve factor for major adverse cardiovascular events in health check-up participants." European Heart Journal 40, Supplement_1 (2019). http://dx.doi.org/10.1093/eurheartj/ehz748.0307.

Full text

Abstract:

Abstract Background/Introduction Health check-up has been carried out for individual health management. One of its main objectives is the early detection and prevention of major adverse cardiovascular event (MACE). Purpose We investigated predictive factors for MACE among clinical test items in health check-up program. Methods A total of 13522 subjects (male=8140, 52.8±12.3 year-old at baseline), who visited our hospital for a health check-up between 2008 and 2015, were enrolled. After the baseline examination, they were followed up until December 2016 (median 1827 days) with the endpoint bein

APA, Harvard, Vancouver, ISO, and other styles

43

Roth, Sebastian, René M’Pembele, Purificación Matute, Katarzyna Kotfis, Jan Larmann, and Giovanna Lurati Buse. "Cardiovascular-Kidney-Metabolic Syndrome: Association with Adverse Events After Major Noncardiac Surgery." Anesthesia & Analgesia, April 5, 2024. http://dx.doi.org/10.1213/ane.0000000000006975.

Full text

Abstract:

BACKGROUND: The American Heart Association (AHA) recently defined the cardiovascular-kidney-metabolic syndrome (CKM) as a new entity to address the complex interactions between heart, kidneys, and metabolism. The aim of this study was to assess the outcome impact of CKM syndrome in patients undergoing noncardiac surgery. METHODS: This is a secondary analysis of a prospective international cohort study including patients aged ≥45 years with increased cardiovascular risk undergoing noncardiac surgery. Main exposure was CKM syndrome according to the AHA definition. The primary end point was a com

APA, Harvard, Vancouver, ISO, and other styles

44

Dharan, Ajay S., Lachlan L. Dalli, Muideen T. Olaiya, et al. "Risk Factors Associated With Major Adverse Cardiovascular Events After Ischemic Stroke: A Linked Registry Study." Neuroepidemiology, December 19, 2023. http://dx.doi.org/10.1159/000535872.

Full text

Abstract:

Introduction: Survivors of stroke are at risk of experiencing subsequent major adverse cardiovascular events (MACEs). We aimed to determine the incidence of, and risk factors for, MACE after first-ever ischemic stroke, by age group (18–64 years vs ≥65 years). Methods: Observational cohort study using patient-level data from the Australian Stroke Clinical Registry (2009–2013), linked with hospital administrative data. We included adults with first-ever ischemic stroke who had no previous acute cardiovascular admissions and followed these patients for two years post-discharge, or until the first

APA, Harvard, Vancouver, ISO, and other styles

45

Kaur, Ravinder Jeet, Byron H. Smith, Shafaq R. Rizvi, et al. "SUN-624 Low Risk of Major Adverse Cardiovascular Events After Pancreas Transplantation Alone." Journal of the Endocrine Society 4, Supplement_1 (2020). http://dx.doi.org/10.1210/jendso/bvaa046.1791.

Full text

Abstract:

Abstract INTRODUCTION: Type 1 Diabetes (T1D) patients have an increased risk for major adverse cardiovascular events (MACE). Pancreas Transplantation Alone (PTA) in patients with T1D achieves near normal glucose control for a prolonged period but limited data are available to date regarding MACE during a 10 year follow up period after the procedure. OBJECTIVE: We studied incidence of MACE after PTA in T1D patients over a 10 year follow-up period. METHODS: Retrospectively, we studied 113 T1D recipients of PTA at Mayo Clinic, Rochester with the procedure performed between January 1998 and August

APA, Harvard, Vancouver, ISO, and other styles

46

Imperiali, Claudia E., Juan C. Lopez-Delgado, Macarena Dastis-Arias, and Lourdes Sanchez-Navarro. "Biomaker evaluation for major adverse cardiovascular event development in patients undergoing cardiac Surgery." Advances in Laboratory Medicine / Avances en Medicina de Laboratorio, July 25, 2020. http://dx.doi.org/10.1515/almed-2020-0031.

Full text

Abstract:

AbstractObjectivesThe postoperative period of cardiac surgery (CS) is associated with the development of major adverse cardiovascular events (MACEs). However, the evaluation of MACE after CS by means of biomarkers is poorly developed. We aimed to evaluate postoperative biomarkers that could be associated with MACE.MethodsTwo Hundred and ten patients who underwent CS were enrolled during the study period. The diagnosis of MACE was defined as the presence of at least one of the following complications: acute myocardial infarction, heart failure, stroke presented during intensive care unit (ICU)

APA, Harvard, Vancouver, ISO, and other styles

47

Bitar, Wisam, Jaako Helve, Mikko Haapio, Virpi Rauta, Eero Olavi Honkanen, and Patrik Finne. "#3940 RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS ACCORDING TO DIALYSIS MODALITY." Nephrology Dialysis Transplantation 38, Supplement_1 (2023). http://dx.doi.org/10.1093/ndt/gfad063a_3940.

Full text

Abstract:

Abstract Background and Aims Among dialysis patients, cardiovascular events are the leading cause of death. Little is known about difference in the frequency of cardiovascular events between various dialysis modalities. Glucose load may contribute to a metabolic burden in peritoneal dialysis (PD). On the other hand, hemodialysis can cause intradialytic hypotension, cardiac stunning, and arrhythmias, which are associated with increased risk of death. We compared risk of major cardiovascular events in patients who started continuous ambulatory PD (CAPD), automated PD (APD) and home HD with in-ce

APA, Harvard, Vancouver, ISO, and other styles

48

Fialho, I., C. Mateus, M. Passos, et al. "Predictors of major adverse cardiovascular events in patients with severe aortic stenosis awaiting aortic valve replacement." European Heart Journal 44, Supplement_2 (2023). http://dx.doi.org/10.1093/eurheartj/ehad655.1633.

Full text

Abstract:

Abstract Background Severe aortic stenosis (AS) is a progressive disease associated with an increased risk of heart failure (HF) and mortality if left untreated. Aortic valve replacement (AVR) is the treatment of choice. However, it is not always immediately available, and some patients have experienced major cardiovascular events (MACE) while waiting for AVR. The identification of reliable predictors of MACE can help clinicians risk-stratify severe AS patients and tailor their management to prevent adverse outcomes. Purpose We aimed to evaluate predictors of MACE in real-world patients with s

APA, Harvard, Vancouver, ISO, and other styles

49

Gaszner, B., J. Szigeti, M. Banfi, et al. "Arterial stiffness for predicting major adverse cardiovascular events in post-infarcted patients." European Heart Journal 45, Supplement_1 (2024). http://dx.doi.org/10.1093/eurheartj/ehae666.2745.

Full text

Abstract:

Abstract Introduction According to recent 2021 ESC prevention guidelines arterial stiffness (aortic pulse wave velocity –PWV, augmentation index - Aix) predicts future major adverse cardiovascular events (MACE). Both parameters have a prognostic relevance in different patient population (hypertension, diabetes, chronic kidney disease), however in post-infarcted, very high cardiovascular risk population the exact prognostic value for PWV and Aix needs to be clarify. Purpose We evaluated PWV and Aix cut-off values for MACE prediction and validated the prognostic relevance of high stiffness param

APA, Harvard, Vancouver, ISO, and other styles

50

Lee, E., B. Tan, Y. H. Chin, et al. "Insights into the reporting of major adverse cardiovascular events in coronary artery disease trials." European Heart Journal 45, Supplement_1 (2024). http://dx.doi.org/10.1093/eurheartj/ehae666.1556.

Full text

Abstract:

Abstract Background and Purpose Major adverse cardiovascular event (MACE) is one of the most used composite outcomes in coronary artery disease (CAD) trials, though its lack of a standardised definition has led to ambiguity and challenges in its interpretation. This study aims to elucidate the definition of MACE and guide future interpretation of MACE in the context of CAD trials. Methods A systematic review was conducted by searching Medline, Embase and Cochrane for double-blind pharmacological randomized-controlled trials among participants with CAD from 2012 to 2022 that reported MACE outco

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!